SonoThera

SonoThera is a biotechnology company dedicated to developing innovative ultrasound-guided nonviral gene therapy platforms. Founded by Dr. Steve Feinstein, Dr. Michael Davidson, and Kenneth Greenberg, the company focuses on enhancing the safety, efficacy, and cost-effectiveness of gene therapy. SonoThera utilizes microbubbles and ultrasound technology to deliver genetic medicines to various human organs. The company's primary service involves a non-invasive platform that uses microbubbles to deliver nucleic acid payloads to targeted sites within the body. By injecting microbubbles into the bloodstream and employing an FDA-cleared ultrasound device, SonoThera can guide these microbubbles to specific locations, creating transient pores in cell membranes for genetic material entry. SonoThera is developing genetic medicines aimed at treating chronic kidney diseases, hematologic disorders, neurodegenerative diseases, and certain cardiovascular conditions. SonoThera has secured significant funding from notable investors, including ARCH Venture Partners and Johnson & Johnson Innovation, and is actively seeking partnerships with biopharma companies to advance its development and commercialization efforts.